Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
203.75
+2.61 (1.30%)
At close: Apr 24, 2026, 4:00 PM EDT
203.31
-0.44 (-0.22%)
After-hours: Apr 24, 2026, 7:55 PM EDT
Natera Revenue
In the year 2025, Natera had annual revenue of $2.31B with 35.90% growth. Natera had revenue of $665.50M in the quarter ending December 31, 2025, with 39.79% growth.
Revenue (ttm)
$2.31B
Revenue Growth
+35.90%
P/S Ratio
12.52
Revenue / Employee
$375,588
Employees
6,140
Market Cap
28.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.31B | 609.20M | 35.90% |
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.98% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
| Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
| Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
| Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
| Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
| Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
| Dec 31, 2013 | 55.17M | 40.92M | 287.16% |
| Dec 31, 2012 | 14.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.31B |
| Labcorp Holdings | 13.95B |
| Quest Diagnostics | 11.28B |
| Agilent Technologies | 7.07B |
| Illumina | 4.34B |
| IDEXX Laboratories | 4.30B |
| Mettler-Toledo International | 4.03B |
| Waters | 3.17B |
NTRA News
- 4 days ago - Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT - Business Wire
- 12 days ago - Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst - Benzinga
- 13 days ago - Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - Business Wire
- 17 days ago - Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents - Business Wire
- 19 days ago - 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform - Business Wire
- 26 days ago - Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery - Benzinga
- 26 days ago - SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery - Business Wire
- 5 weeks ago - Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers - Business Wire